|
|
|
|
| LEADER |
01583nam a2200301 u 4500 |
| 001 |
EB002000677 |
| 003 |
EBX01000000000000001163578 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 100 |
1 |
|
|a Kim, Joanne
|
| 245 |
0 |
0 |
|a Ketamine for treatment-resistant depression or post-traumatic stress disorder in various settings
|h Elektronische Ressource
|b a review of clinical effectiveness, safety, and guidelines
|c Joanne Kim, Monika Mierzwinski-Urban
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2017, March 1, 2017
|
| 300 |
|
|
|a 1 PDF file (30 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Ketamine / therapeutic use
|
| 653 |
|
|
|a Stress Disorders, Post-Traumatic / drug therapy
|
| 653 |
|
|
|a Off-Label Use
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Depressive Disorder, Treatment-Resistant / drug therapy
|
| 700 |
1 |
|
|a Mierzwinski-Urban, Monika
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK487457
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a To inform clinical practice on the treatment of patients with TRD or PTSD, this report aimed to provide evidence on the clinical benefits and harms and evidence-based guidelines on the off-label use of ketamine in various settings
|